Globotriaosylceramide

CAS : 71965-57-6

Ref. 3D-OG45939

Informations sur le produit

• Nom: Globotriaosylceramide
• Synonymes: Gb3α-D-Gal-(1→4)-β-D-Gal-(1→4)-β-D-Glc-1→O-ceramideCeramide trihexosides, 71965-57-6, Cd 77, Ceramide trihexoside, Ceramide, 1-O-(O-α-<span class="text-smallcaps">D</smallcap>-galactopyranosyl-(1→4)-O-β-<smallcap>D</smallcap>-galactopyranosyl-(1→4)-β-<smallcap>D</span>-glucopyranosyl)-, Fabry glycolipid, Ganglioside G_L3, Ganglioside Gb₃, Gb₃, Gb₃Cer, Globo-N-triaosylceramide, Globotriglycosylceramide, Globotriosylceramide, Shiga toxin receptor, Trihexosylceramide, Ceramide, 1-O-(O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl)-

Description

It is one of the few clusters of differentiation that is not a protein and structurally contains a galactose moiety linked α to lactosylceramide. Defects in the enzyme α-galactosidase lead to the buildup of globotriaosylceramide, causing Fabry's disease. The pharmaceutical drug migalastat enhances the function of α-galactosidase and is used to treat Fabry's. Globotriaosylceramide is also one of the targets of Shiga toxin, which is responsible for pathogenicity of enterohemorrhagic E. coli.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 1135.79577
• Formule: C₆₀H₁₁₃NO₁₈
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder